ArticleApplied microbiology and biotechnology2025
Engineering human/simian rotavirus VP7 reassortants in the absence of UTR sequence information.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probing the sequence constraints for the stable incorporation of chimeric NSP1 segments into infectious rotaviruses.The Journal of general virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recently developed plasmid-based reverse genetics systems for rotavirus A (RVA) enable rapid engineering of reassortants carrying human RVA antigens. However, complete genome segment sequences are required for successful generation of such reassortants, and sequencing of the untranslated regions (UTRs) of field strains is often not accomplished. To address this problem, we established a system that permits the generation of reassortants using only the open reading frame (ORF) nucleotide sequence information. Plasmids containing the VP7-ORF nucleotide sequence of six human RVA field strains (genotypes G2, G5, G8, G9, G12 and G29) derived from GenBank and flanked by the UTR sequences of simian RVA strain SA11 were constructed. Using these plasmids, four VP7 (G2, G5, G9 and G12) reassortants in an SA11 backbone were successfully generated. In contrast, the G8 and G29 reassortants were not viable. BLASTp search of the G8 and G29 sequences revealed an unusual amino acid substitution in each sequence, which was not present in related field strains. Site-directed reversion of the corresponding C656T mutation in G8 led to effective rescue of reassortant virus. However, reverting the G84C mutation in G29 did not result in replicating virus. The results suggest that most human RVA VP7 UTRs can be substituted with simian RVA UTRs. However, generation of reassortants might be impeded by potential sequencing errors or intrinsic reassortment limitations. The established system could help to broaden the antigenic repertoire for rapid engineering of potential novel RVA vaccine strains. KEY POINTS: • Generation of diverse rotavirus vaccine strains is impeded by missing UTR sequences. • UTRs from SA11 can be used instead of missing UTR sequences from field strains. • Human RVA reassortants of genotypes G2, G5, G8, G9, G12 were successfully rescued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.